| [1] |
田连芬，赖少侣，王铮.影像学预测直肠癌转移淋巴结的研究进展[J].临床放射学杂志，2020，39（3）：623-626.
|
| [2] |
沈新伟，薛大伟，邢丽，等.贝伐珠单抗抗血管生成疗法治疗晚期结直肠癌的临床标志物的研究进展[J].中外医学研究，2020，18（6）：177-179.
|
| [3] |
杨占菊，黄长江，王名雪.以PD-1 和PD-L1 为靶点的肿瘤免疫治疗研究进展[J].癌症进展，2020，18（8）：772-777.
|
| [4] |
徐嘉曼，王大维，王浩，等.MSH3 基因在恶性肿瘤中的研究进展[J].现代口腔医学杂志，2020，34（2）：110-112.
|
| [5] |
黄思佳，邱旭东，李文彦，等.肿瘤微环境中的细胞调控网络及促瘤机制[J].生命科学，2020，32（4）：315-324.
|
| [6] |
Ishida Y，Agata Y，Shibahara K，et al.Induced expression of PD-1，a novel member of the immunoglobulin gene super family，upon programmed cell death[J].EMBO J，1992，11（11）：3887-3895.
|
| [7] |
McDermott DF，Atkins MB.PD-1 as a potential target in cancer therapy[J].Cancer Med，2013，2（5）：662-673.
|
| [8] |
Wei F，Zhang T，Deng SC，et al.PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways[J].Cancer Lett，2019，450：1-13.
|
| [9] |
马宝镇，高全立.抗PD-1 及PD-L1 在肿瘤治疗中的进展[J].中国免疫学杂志，2017，33（5）：796-801.
|
| [10] |
Yassin M，Sadowska Z，Djurhuus D，et al.Upregulation of PD-1 follows tumour development in the AOM/DSS model of inflammation-induced colorectal cancer in mice[J].Immunology，2019，158（1）：35-46.
|
| [11] |
李娜.CT 诊断结肠癌致肠梗阻的临床应用价值评述[J].中国现代药物应用，2016，10（16）：44-45.
|
| [12] |
Cui C，Yu B，Jiang Q，et al.The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers[J].Clin Exp Pharmacol Physiol，2019，46（1）：3-10.
|
| [13] |
Yaghoubi N，Soltani A，Ghazvini K，et al.PD-1/PD-L1 blockade as a novel treatment for colorectal cancer[J].Biomed Pharmacother，2019，110：312-318.
|
| [14] |
Kwon M，Hong JY，Kim ST，et al.Association of serine/threonine kinase 11 mutations and response to programmed cell death 1 inhibitors in metastatic gastric cancer[J].Pathol Res Pract，2020，216（6）：152 947.
|
| [15] |
Song Y，Liu Q，Zuo T，et al.Combined antitumor effects of anti-EGFR variant ⅢCAR-T cell therapy and PD-1 check point blockade on glioblastoma in mouse model[J].Cell Immunol，2020，352：104112.
|
| [16] |
Takada K，Yoneshima Y，Tanaka K，et al.Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors[J].J Cancer Res Clin Oncol，2020，146（5）：1217-1225.
|
| [17] |
Li T，Zhang C，Zhao G，et al.Data analysis of PD-1 antibody in the treatment of melanoma patients[J].Data Brief，2020，30：105 523.
|
| [18] |
Kroemer G，Galluzzi L，Zitvogel L，et al.Colorectal cancer：the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?[J].Oncoimmunology，2015，4（7）：e1058597.
|
| [19] |
Le DT，Uram JN，Wang H，et al.PD-1 Blockade in tumors with mismatch-repair deficiency[J].N Engl J Med，2015，372（26）：2509-2520.
|
| [20] |
Germano G，Lamba S，Rospo G，et al.Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth[J].Nature，2017，552（7683）：116-120.
|
| [21] |
Llosa NJ，Cruise M，Tam A，et al.The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints[J].Cancer Discov，2015，5（1）：43-51.
|
| [22] |
Wherry EJ，Kurachi M.Molecular and cellular insights into T cell exhaustion[J].Nat Rev Immunol，2015，15（8）：486-499.
|
| [23] |
田若曦，孟泽松，王贵英，等.PD-1/PD-L1 抑制剂在结直肠癌治疗中的现状及预后预测[J].肿瘤，2020，40（3）：215-222.
|
| [24] |
Elashi AA，Sasidharan Nair V，Taha RZ，et al.DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients[J].Oncoimmunology，2019，8（2）：e1542918.
|
| [25] |
Liu DX，Li DD，He W，et al.PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer[J].Oncoimmunology，2020，9（1）：e1711650.
|
| [26] |
Limagne E，Thibaudin M，Nuttin L，et al.Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages[J].Cancer Immunol Res，2019，7（12）：1958-1969.
|
| [27] |
Lv J，Jia Y，Li J，et al.Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour micro environment[J].Cell Death Dis，2019，10（6）：415.
|
| [28] |
Floudas CS，Brar G，Mabry-Hrones D，et al.A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer[J].Clin Colorectal Cancer，2019，18（4）：e349-e360.
|
| [29] |
石亮荣.射频消融与PD-1 单抗的协同抗肿瘤作用[D].苏州：苏州大学，2015.
|
| [30] |
Janikovits J，Müller M，Krzykalla J，et al.High numbers of PDCD1 （PD-1）-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer[J].Oncoimmunology，2018，7（2）：e1390640.
|
| [31] |
Ahtiainen M，Wirta EV，Kuopio T，et al.Combined prognostic value of CD274 （PD-L1）/PDCDI （PD-1）expression and immune cell infiltration in colorectal cancer as per mismatch repair status[J].Mod Pathol，2019，32（6）：866-883.
|
| [32] |
Tomé M，Pappalardo A，Soulet F，et al.Inactivation of Proprotein Convertases in T Cells Inhibits PD-1 Expression and Creates a Favorable Immune Microenvironment in Colorectal Cancer[J].Cancer Res，2019，79（19）：5008-5021.
|
| [33] |
Shi W，Dong L，Sun Q，et al.Follicular helper T cells promote the effector functions of CD8+T cells via the provision of IL-21，which is downregulated due to PD-1/PDL1-mediated suppression in colorectal cancer[J].Exp Cell Res，2018，372（1）：35-42.
|
| [34] |
Oliveira AF，Bretes L，Furtado I.Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer[J].Front Oncol，2019，9：396.
|
